INTRODUCTION
Hodgkin (HL) and non-Hodgkin lymphoma (NHL) constitute a biologically heterogeneous group of commonly-occurring hematological malignancies with marked variability in clinical behavior, treatment approaches and response to conventional therapy. Autologous hematopoietic stem-cell transplantation (ASCT) is a useful therapeutic modality for many patients with relapsed HL and relapsed or high-risk NHL. Patients with relapsed/refractory HL who received high-dose therapy (HDT) and ASCT as compared with conventional salvage chemotherapy also experienced improved outcomes. [1] [2] [3] [4] Prospective randomized trials and several retrospective studies have demonstrated improved outcomes when ASCT is utilized for consolidation following salvage chemotherapy in patients with relapsed aggressive NHL. [5] [6] [7] [8] [9] [10] A randomized trial also showed that ASCT benefited patients with relapsed follicular lymphoma (FL) 11 , which was further supported by registry data. 12 HDT and ASCT as initial therapy for patients with mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) with high-risk international prognostic index (IPI) remains controversial, but has been commonly used. [13] [14] [15] [16] [17] [18] At present, however, only limited data suggest any specific HDT regimen offers benefits over alternatives. [19] [20] [21] [22] [23] [24] Busulfan (Bu), an alkylating agent, has been shown to be an effective component of the conditioning regimen for myeloablative autologous and allogeneic hematopoietic stem cell transplantation. 1, 4, 7, [25] [26] [27] [28] [29] One of the theoretical advantages of Bu-based HDT regimens over alternatives is that methods for monitoring plasma concentrations have been well established and individualized dosing is therefore possible. 30 Pharmacokinetic (PK)-directed dose adjustment for Bu was originally developed to avoid unpredictable overexposure and resultant unfavorable adverse effects such as vomiting and veno-occlusive disease of the liver (VOD; sinusoid obstruction syndrome), especially when Bu was available only in an oral formulation. 25, 27, 30 The introduction of intravenous (IV) Bu bypasses the problem of variable drug absorption from the gastrointestinal tract, which has reduced the incidence of adverse events (AEs). Moreover, single-institution studies showed improvement in overall survival (OS) for patients with NHL when oral Bu was replaced by IV Bu in HDT conditioning for ASCT, 25, 27, 31 but multicenter data are lacking. This phase 2 trial was designed to examine conditioning with a PK-directed dosing regimen for IV Bu combined with cyclophosphamide and etoposide (BuCyE) in a multicenter setting and to compare this approach to conditioning with carmustine, etoposide, cytarabine and melphalan (BEAM) using data collected from the Center for International Blood and Marrow Transplant Research (CIBMTR).
MATERIALS AND METHODS

Study Design
This prospective, multicenter, single-arm, phase 2 study investigated the safety and efficacy of an IV BuCyE regimen with PK-directed Bu dosing. The primary objective was to evaluate the clinical outcomes including progression-free survival (PFS; primary endpoint), overall survival (OS), transplant-related mortality (TRM) and overall response rate. TRM was defined as a death after transplant due to any cause other than disease progression. Toxicity was defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3. The secondary objective was to compare the clinical outcomes of subjects receiving the BuCyE regimen with those receiving a conditioning regimen with BEAM from centers not participating in this clinical trial, as obtained from CIBMTR registry data. 5, 6, 12, 32 CIBMTR data management procedures have been described previously. 33 In addition, the accuracy of PK-directed BU dose adjustment utilizing the test-dose method was evaluated.
Study Eligibility
Eligible subjects were those who required first ASCT for HL and B-cell NHL. All subjects had relapsed disease after initial therapy or were initially refractory to an anthracyclinebased chemotherapy and had achieved complete remission (CR) or partial remission (PR) following salvage chemotherapy according to the Cheson criteria. 34 Additionally, subjects with NHL with IPI 35 score 4-5, or MCL were eligible for study treatment as a part of primary therapy. All subjects were required to have had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with at least 2 × 10 6 CD34 + cells/kg previously stored. Patients with major organ dysfunction or prior treatment with Bu or gemtuzumab ozogamicin were excluded. The study initially enrolled subjects of 18-80 years, but the protocol was amended to reduce the upper age limit to 65 years due to a high TRM rate at 100 days post-transplant for subjects aged >65 years. All subjects provided written informed consent in accordance with the Declaration of Helsinki principles to participate in this study. The trial was registered at www.clinicaltrials.gov as NCT00948090. The same eligibility criteria were applied to the comparator group, selecting patients aged 18-65 years who had received ASCT with BEAM conditioning from 2008 to 2010 in US and Canadian transplant centers not participating in the above mentioned clinical trial and who were registered with CIBMTR.
PK-Directed Dose Adjustment of Busulfan
The method of adjusting busulfan dose per patient via individual PK parameters has been reported previously. 36 In brief, six serial blood samples were collected in sodium heparin tubes after administration of the IV Bu test dose (initial therapeutic drug monitoring [TDM] ) and the first individualized conditioning dose on day −8 (confirmatory TDM). For the initial TDM, a test dose of IV BU (0.8 mg/kg) was administered over 2 hours between days −14 and −11. This dose was intended to achieve an area-under-the-curve (AUC) of 1000-1500 μM•min. Blood samples were collected at the end of the 2-hour infusion and 15, 30, 120, 180 and 240 minutes thereafter. For the confirmatory TDM on day −8, individual IV Bu doses were calculated to achieve a total AUC of 20,000 μM•min, including the AUC from the test and confirmatory doses. 4, 30 Samples for confirmatory TDM were collected at the end of the 3-hour infusion and 30, 90, 180 and 300 minutes thereafter.
The first sample for both the test dose and confirmatory TDM were drawn at the end of the infusion and no samples were drawn during the infusion. Samples were stored on wet-ice or refrigerated immediately after collection, centrifuged at 4°C, and stored at −20°C or below until shipping. To allow same day sample shipping and expedite availability of PK results, test dose and confirmatory TDM sampling were limited to 240 and 300 minutes after the end of infusion, respectively. Standard sampling timepoints were utilized for the test dose, based on 0.8 mg/kg every 6 hours sampling schedule. [37] [38] [39] For the confirmatory TDM sampling, Bu clearance and AUC estimates have been shown to be comparable from PK sampling over 8 (300 minutes after the end of infusion),11, and 24 hours after the start of infusion for every 24 hour administration and, thus, sampling was limited to 300 minutes after the end of infusion. 40 The pharmacokinetics laboratory at the Seattle Cancer Care Alliance (SCCA) measured plasma Bu concentrations and recommended individualized Bu dosing. Concentrations were analyzed by gas chromatography with mass selective detection as previously described. 41 The dynamic range was from 62 to 4500 ng/mL and the intraday and interday coefficient of variations were less than 5% and 8%, respectively. Bu AUC from time 0 to infinity and its estimated corresponding clearance were determined using a one-compartment first-order elimination model via WinNonlin® version 5.2 (Pharsight, Sunnyvale, CA, USA). 38, 40 Targeted daily AUC during the conditioning regimen was calculated as follows:
The conditioning regimen daily busulfan dose was then calculated as follows:
Accuracy of the test dose prediction was assessed by the percent error calculation:
Accuracy of the dose adjustment was assessed by the percent error calculation:
Conditioning Regimen With BuCyE
The conditioning regimen consisted of PK-directed doses of Bu on days −8 through −5 (see previous section), etoposide 1.4 g/m 2 on day −4 and cyclophosphamide 2.5 g/m 2 on days −3 and −2, followed by stem-cell infusion on day 0. Individualized doses of IV Bu were administered over 3 hours once daily. IV Bu doses on days −6 and −5 were modified only when the second PK results on day −8 indicated further adjustment were required to achieve Bu exposure of 20,000 μM•min (± 20%; cumulative Bu exposure between 16,000 to 24,000 μM•min). Although no seizure prophylaxis was instituted during the test dose of IV Bu administration, benzodiazepines and/or levetiracetam were used as anti-seizure medications for conditioning. Peritransplant palifermin and post-transplant use of colony-stimulating factor use were not restricted.
Statistical Analysis
The endpoints of PFS and OS were depicted graphically by Kaplan-Meier curves. Median survival in months, with 95% confidence intervals, as well as one-and two-year survival rates were also estimated. Disease responses were summarized by frequency and percentage at each of the specified time points. Efficacy analyses were based on the modified ITT data set.
This study had a pre-specified endpoint (as described in the approved clinical protocol) comparing efficacy of BuCyE with BEAM from CIBMTR registry data. Baseline characteristics of patients enrolled in this clinical trial 65 years of age or younger were used to match with CIBMTR controls. All patients from the phase 2 study selected for efficacy analyses were matched with up to four patients treated with BEAM obtained from CIBMTR to provide approximately 80% power to demonstrate 11% difference in the 2-year PFS rate, assuming that the 2-year PFS rates for BuCyE and BEAM were 66% and 55%, respectively. 24, 42 The four criteria used for matching were: age ± 10 years, Karnofsky Performance Score (≥ 90%, < 90%), disease status prior to transplant as defined above (CR1, CR2 or higher, PR) and histology (HL, FL, DLBCL, MCL, Burkitt, and others). All patients were followed-up for at least 1 year until May 2013, which provided an approximate median 2-year follow-up for this study. Follow-up visits were timed to match the CIBMTR registry follow-up time points for data comparability: day 100, 6 months, 1 year, and every year after 1 year.
Baseline characteristics at transplantation were tabulated and compared for the phase 2 BuCyE group and the matched CIBMTR cohort conditioned with BEAM. Outcomes were tabulated for patients in the phase 2 BuCyE trial and compared with the matched BEAM patients from the CIBMTR. Survival curves were constructed using the Kaplan-Meier method and were compared by a two-sided log-rank test. Multivariable Cox regression analyses were conducted to compare clinical outcomes after HCT between BuCyE and BEAM. To account for the intra-cluster correlation resulting from covariates matching, marginal models approach were used in all comparisons. Marginal Cox models 43 were used to evaluate prognostic factors for PFS, TRM and OS. The proportional hazards assumption was met. An interaction test indicated a differential effect of conditioning regimen by disease type on PFS; therefore, the comparisons are presented by disease type. A level of significance (α) of 0.05 was defined as statistically significant. All statistics were computed using SAS 9.3.
RESULTS
Patient Disposition and Demographics
A total of 207 subjects with HL (n=66) or NHL (n=141) were enrolled from 32 centers in the US and Canada between February 2010 and April 2012. Four subjects did not proceed with ASCT due to insurance or eligibility issues. One patient who experienced a syncopal episode after etoposide administration was not treated with cyclophosphamide and discontinued from the study on day −1. This patient was included in the intent-to-treat population, as stem cells were infused as planned. In addition, four patients were identified as ineligible, but were included in the intent-to-treat analyses. These included: T-cell lymphoma (n=1), failure to confirm CR or PR (n=1), history of hepatitis C (n=1), and a patient with FL who did not receive prior anthracycline (n=1). The study initially enrolled subjects of 18-80 years, but the protocol was amended to reduce the upper age limit to 65 years due to a high TRM rate at 100 days post-transplant for subjects >65 years. We report safety for all the subjects undergoing ASCT (n=203) and efficacy from those aged ≤ 65 years (n=186), and recipients of BuCyE who were matched to up to a maximum of 4 BEAM patients yielding a total of 729 controls.
At baseline, 67% of subjects were male, 87% were Caucasian and 6% were African American, and 96% had an ECOG performance status of 0-1 (Table 1) . Median time from initial diagnosis to the autologous transplant was 18.4 months (range: 71 days to 262 months). Lymphoma subtypes and disease status at transplantation are described in Table 1 .
PK-Directed Dose Adjustment of Busulfan
Of the 203 subjects undergoing ASCT in the present study, 200 subjects used individualized Bu doses determined by initial TDM, whereas three subjects used 3.2 mg/kg on days −8 and −7 due to non-evaluable test PK results. Confirmatory TDM samples were collected from 203 subjects on day −8 (n=201) or day −7 (n=2). In one subject, confirmatory TDM was equivocal and not utilized. Consequently, 199 subjects had two sets of evaluable PK parameters obtained with initial and confirmatory TDM.
Among the 199 subjects, median Bu clearance calculated from initial TDM was 2.98 ml/min/kg (range 1.95-4.39 ml/min/kg). Overall, 2.9% of subjects had an AUC of >1,500 μM•min and 32.8% of subjects had an AUC of <1,000 μM•min (Figure 1 ). In total, 35.8% of subjects would likely have been outside the AUC target range if weight-based dosing had been used without TDM. A greater proportion of obese (BMI ≥30) or overweight (BMI = 25.0-29.9) subjects were underexposed to Bu compared with those with normal BMI (BMI = 18.5-24.9) ( Table 2 ). However, stratification by BMI was not sufficient to identify any specific patient population that would not have required TDM. After PK-directed dose adjustments, 95.0% of subjects fell within the target range for total AUC after PK-directed dose adjustments based on initial and confirmatory PK (AUC = 20,000 μM•min ± 20%, Figure 2 ); 3.0% and 2.0% subjects required additional dose reductions and increases for the last 2 days respectively. Mean absolute error for the test dose predicted AUC day-8 (confirmatory PK) was 7.4% (95% CI 6.5 to 8.3%). Evaluating the accuracy of test PKbased dose adjustments based on the margin of error from the desired daily target exposure, mean absolute error was 7.5% (95% CI 6.5 to 8.4%). No significant change in clearance was observed between test PK and confirmatory PK (p=0.220, paired t-test), indicating that intrapatient variability in clearance was minimal. Median total IV Bu administered was 14.5 mg/kg of actual body weight (range: 8.8-20.1 mg/kg). Busulfan exposure was similar to the overall population in the subgroup of patients experiencing the AEs of TRM or mucositis (Figure 3 ).
Adverse Events
An early subset-analysis by age in June 2011 revealed that four of 17 subjects >65 years suffered TRM by day 100 which met a protocol-specified stopping rule for this population. The TRM rates by day 100 for all subjects (n=203), patients >65 years (n=17), and patients ≤65 years (n=186) were 4.5% (95% confidence intervals [CI)]: 2.1-8.3%), 23.5% (95% CI: 6.8-49.9%) and 2.7% (95% CI: 0.9-6.2%), respectively. The most common AEs leading to death were respiratory failure (4 subjects, 1.9%), sepsis (3 subjects, 1.4%), multi-organ failure (2 subjects, 1.0%), and acute respiratory distress syndrome (2 subjects, 1.0%). Serious AEs with an incidence of 2% or greater were recorded for 90 (43.5%) subjects. The most common grade 3/4 AEs observed in subjects ≤65 years were febrile neutropenia (Grade 3: 54%; 4: 3%), stomatitis (Grade 3: 41%; 4: 0%), nausea (Grade 3: 10%; 4: 0%), and pneumonia (Grade 3: 7% ; 4:0%). There were no instances of seizure or hepatic VOD based on Baltimore criteria. 44 Other grade ≥3 AEs are listed in Table 3 .
Efficacy of BuCyE
Efficacy was analyzed for 186 subjects ≤65 years old with HL (n=65) or NHL (n=121), including: DLBCL (n=63), MCL (n=29) and FL (n=23). Of the 186 patients, 156 (84%) underwent transplant in PR or CR2 or higher. The remainder (n=30) underwent ASCT in CR1/CRu1, including 19 patients with MCL. With median follow-up of 20 months, the estimated 2-year PFS was 33% for HL and 58%, 77% and 43% for DLBCL, MCL and FL, respectively. The estimated 2-year OS was 76% for HL and 65%, 89% and 89% for DLBCL, MCL and FL, respectively. The OS and PFS curves for the phase 2 study of PK-directed BuCyE are shown in Figures 4 and 5 , respectively.
Comparisons of BuCyE with Matched CIBMTR Patients
Of the 186 patients, 183 recipients of BuCyE with lymphoma in complete or partial response were matched at a maximum ratio of 4:1 with 729 CIBMTR controls based on age, performance status, disease status prior to transplant and lymphoma histology. No matches were found for three patients. In total, 177 cases had 4 matched controls, and 97% of controls had an age difference from controls of ≤ 5 years. A comparison of patients from the phase 2 trial of BuCyE and the matched cohort of patients conditioned with BEAM from the CIBMTR is shown in Table 4 . Patients were well-matched for age, performance status, histologic subtype and response prior to transplant, and the median follow up was 22 months in both cohorts. Two-year cumulative incidences of TRM were 3.3% (95% CI: 1.4-6.6%) and 3.9% (95% CI: 2.4-5.7%) for BuCyE and BEAM, respectively. Corresponding 2-year probabilities of OS were 76% (95% CI: 68-82%) and 78% (95% CI: 74-82%). Tables 5 and 6 compare outcomes for NHL and HL separately. Multivariate analysis demonstrated a significant interaction between disease and conditioning regimen in evaluation of disease progression and treatment failure. Analyses by histology demonstrated that among patients with NHL, there were no differences in outcomes between groups. Among patients with HL treated with BuCyE or BEAM, respectively, the 2-year cumulative incidence of progression was 66% (95% CI: 53-77%) and 38% (95% CI: 31-45%) and 2-year PFS was 33% (95% CI: 21-46%) and 59% (95% CI: 52-66%), with no difference in TRM or OS. The 2-year cumulative incidences of TRM were 3.3% (95% CI: 1.4-6.6%) and 3.9% (95% CI: 2.4-5.7%) for BuCyE and BEAM, respectively. Survival curves comparing BuCyE and BEAM conditioning from this matched analysis for NHL and HL are shown in Figures 6 and 7 .
DISCUSSION
This was the first large-scale, multicenter, prospective study in North America in which the IV weight-based Bu dose was further adjusted based on PK results from a pre-conditioning test dose. We found that simple pre-conditioning TDM accurately estimated Bu clearance, allowing for adequate conditioning dosing. Accuracy of the test dose prediction and accuracy of test dose-based dose adjustments were high, comparable to previous studies in which clearance remained consistent across a preconditioning test PK and a conditioning regimen for oral and IV Bu. [45] [46] [47] Although infusion rates differed between the test dose and the first therapeutic dose by approximately 2-to 4-fold, infusion rate-dependent nonlinear behavior was not noted. This may be due to determination of Bu AUC and its estimated corresponding clearance using a one-compartment model versus noncompartmental analysis. Bu AUC estimates appear to more variable using noncompartmental analysis. 40 In addition, a population PK analysis demonstrated that Bu PK can be adequately described by a linear PK model without inter-occasional variability. 48 In this study, more than one-third of patients would have had suboptimal exposure to IV Bu if weight-based dosing alone had been used for conditioning, whereas 95% of subjects achieved the target range of Bu exposure after the introduction of individualized TDM. A pre-conditioning test dose may be more convenient for transplant centers relying on external PK laboratories and can offer another opportunity for TDM on the first day of conditioning if the initial PK results are not evaluable.
Results from the present study further showed that such PK-directed Bu doses in combination with cyclophosphamide and etoposide constituted a tolerable regimen for lymphoma patients <65 years of age and was associated with expected transplant conditioning toxicities and a TRM <5%. BuCyE was not well tolerated in patients ≥65 years, resulting in unacceptable early TRM for older patients with lymphoma. For patients with NHL, PK-directed IV BuCyE produced similar PFS and OS to contemporary patients treated with BEAM; however, a statistically significant difference in PFS was observed between BuCyE and BEAM in subjects with HL, indicating superior outcomes for BEAM in terms of relapse and PFS. Although this trial and the additional matched cohort study design were not originally powered to test the difference between the BuCyE and BEAM arms for subjects with HL, the sample size for the phase 2 cohort subset and the 4:1 matching approach were reasonably large for examining this comparison and strength of the association warrants notice.
Previous clinical data using Bu and cyclophosphamide with or without etoposide have yielded clinical results that are comparable to the other preparative regimens for ASCT in both NHL and HL. 4, 7, 24, 26, 27, 29, 30 Bu exposure (as assessed by AUC) has been associated with differences in survival and AEs. Kebriaei and colleagues showed that an optimallydosed group had a significantly better survival rate than those with lower or higher exposures. Fixed-dose IV Bu administration resulted in two thirds of all the subjects achieving AUC values within the optimal window, but PK-directed dosing increased the frequency of patients within the targeted range of AUC exposure up to 95%. The 2-year OS and PFS were 85% and 57%, respectively, for patients with HL, and 67% and 64%, respectively, for patients with NHL. 49 While the outcomes associated with BuCyE for NHL appear similar to BEAM in the present matched analysis, this is not the case for HL.
One common concern of Bu-based conditioning for patients with HL has been the possibility of overlapping toxicity with prior HL therapies such as bleomycin, prior alkylating agents and radiation. However, our findings do not suggest poor outcomes from BuCyE due to excess toxicity or TRM. Indeed, day-28 and day-100 TRM rates were 0% and 1.6%, respectively, for HL patients who received BuCyE conditioning. The primary differences observed between BuCyE and BEAM in this analysis of HL patients was an increase in early relapses, suggesting that BuCyE may be an inferior regimen for disease control among patients with relapsed HL. Why this regimen would produce worse PFS in HL but not in NHL or any NHL subtype remains unclear. A prior single institution study of 72 patients with HL or NHL conditioned with either cyclophosphamide, etoposide, carmustine (CEB) or BEAM found a higher prevalence diarrhea in the BEAM group (81 vs. 51%, P = .0026), but higher OS with BEAM than with CEB (84 vs. 60%); however, outcomes were not stratified by lymphoma subtype. 50 Chen et al. compared outcomes after ASCT across different conditioning regimens and among patients with HL, and busulfanbased regimens were also associated with inferior outcomes. 51 Interpretation of our findings should also consider the limitations of a non-randomized comparison between the cases and controls. Despite constructing a matched cohort of CIBMTR patients for comparison, unmeasured but important factors could be unbalanced between the two groups, which could bias the interventions. Nevertheless, the matching strategy effectively identified a large, contemporary cohort of patients who were similar in age, performance status and lymphoma subtype, which were previously identified as important determinants of outcome. Additionally, the control cohort patients were from centers not participating in the clinical trial, which minimized selection bias.
At present, identifying the preferred therapy for relapsed HL remains complex, and the most effective form of HDT may differ by patient characteristics. Nevertheless, given the dearth of randomized controlled trials to inform the management of patients with relapsed HL undergoing ASCT, careful consideration of these findings should be undertaken and BEAM conditioning should be preferred for patients with HL undergoing ASCT when all other factors are equivalent.
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